Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers August 14, 2018
Pharmacy Choice - News - U.S. Pharmaceutical Industry - August 14, 2018

Pharmacy News

 U.S. Pharmaceutical Industry
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

8/14/18 - Acasti Pharma Provides Business Update for the First Quarter of Fiscal 2019
Acasti Pharma Inc., a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre for the treatment of severe hypertriglyceridemia, today provided a business update and announced its operating and financial results for the first quarter ending June 30, 2018. Jan D Alvise, p
8/14/18 - AcelRx Pharmaceuticals Announces Full Exercise of Underwriters' Option to Purchase Additional Shares
REDWOOD CITY- AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on innovative therapies for use in medically supervised settings, today announced that the underwriters of its previously announced underwritten public offering have exercised in full their option to purchase an additional 1,090,909 shares of AcelRx's common...
8/14/18 - Acorda Announces Management Transitions
Acorda Therapeutics, Inc. today announced that Rick Batycky, Ph.D., Chief Technology Officer, will be leaving Acorda as of August 20, 2018 to take a position as the CEO of a private, venture-backed biotechnology company. David Lawrence, Acorda s Chief of Business Operations, will assume responsibility for the company s Chelsea, MA manufacturi
8/14/18 - ActiGraph Announces New Scientific Affairs and Data Management Division
Guided by the novel endpoint development framework released by the Clinical Trials Transformation Initiative in 2017, ActiGraph's Scientific Affairs and Data Management division, headed by Director Tyler Guthrie, will facilitate joint research and development projects involving corporate partners and subject matter experts from within the...
8/14/18 - Action begins toward lowering drug prices [All Iraq News Agency (AIN)]
But experts who pay close attention to federal drug policy and Medicare rules say the administration is preparing to incrementally roll out a multipronged plan that tasks the Centers for Medicare& Medicaid Services and the Food and Drug Administration with promoting competition, attacking the complicated drug rebate system and introducing tactics t
8/14/18 - Acura Pharmaceuticals Announces Second Quarter 2018 Financial Results
Acura Pharmaceuticals, Inc., a specialty pharmaceutical company innovating abuse deterrent drugs, announced today financial results for the three and six months ended June 30, 2018.. The Company reported a net loss of $2.8 million or $0.13 per diluted share for the six months ended June 30, 2018, compared to a net loss of $1.7 million or $0.15 pe
8/14/18 - Adherium Launches Hailie Solution Direct-to-Consumer in the U.S. for Better Asthma and COPD Management [Sport360]
-Adherium, a leading digital health platform that focuses on improving medication adherence and patient outcomes, today officially launched the Hailie solution in the U.S., following its recent Food and Drug Administration 510 over-the-counter clearance to enable sales direct to consumers. Adherium believes health technology should be simple to use
8/14/18 - Aerpio Reports Second Quarter 2018 Financial Results and Provides Business Update
Aerpio Pharmaceuticals, Inc., a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, today reported financial results for the second quarter ended June 30, 2018 and provided a business update. We had a busy and productive second quarter at Aerpio, commented Stephen Hoffman, M.D. Second, we completed an
8/14/18 - Aeterna Zentaris Reports Second Quarter 2018 Financial and Operating Results
CHARLESTON- Aeterna Zentaris Inc., a biopharmaceutical company engaged in developing and commercializing pharmaceutical products, today reported financial and operating results for the second quarter ended June 30, 2018. Aeterna Zentaris Inc. is a biopharmaceutical company focused on developing and commercializing, principally through...
8/14/18 - Aevi Genomic Medicine Announces Completion of Enrollment in Part A of Phase 2 ASCEND Trial in ADHD
Aevi Genomic Medicine, Inc. today announced that it has completed enrollment in Part A of its Phase 2 ASCEND clinical trial, which is assessing a mGluR mutation positive genetic subset of pediatric and adolescent patients with Attention Deficit Hyperactivity Disorder, to confirm response to AEVI-001 in these patients. "We are pleased that we hav
8/14/18 - AIT Therapeutics Announces $20 Million Common Stock Purchase Agreement with Institutional Investor, Lincoln Park Capital Fund [DesignMENA.com]
-AIT Therapeutics, Inc., a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide for the treatment of patients with respiratory conditions including serious lung infections and pulmonary hypertension, announced today that it has entered into a common stock purchase agreement and registration rights..
8/14/18 - AIT Therapeutics Reports Financial Results for First Fiscal Quarter 2019
AIT Therapeutics, Inc., a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide for the treatment of patients with respiratory conditions including serious lung infections and pulmonary hypertension, today announced financial results for the fiscal first quarter ended June 30, 2018.
8/14/18 - Albireo to Present at Wedbush PacGrow Healthcare Conference
BOSTON- Albireo Pharma, Inc., a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, is scheduled to present at the Wedbush PacGrow Healthcare Conference at the Parker New York in New York City on Tuesday, August 14, 2018, at 8:35 a.m. ED
8/14/18 - Allena Pharmaceuticals to Present at 2018 Wedbush PacGrow Healthcare Conference
NEWTON- Allena Pharmaceuticals, Inc., a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that Louis Brenner, M.D., Allena's President and Chief Operating Officer, will present a company...
8/14/18 - Allogene Therapeutics Appoints Susie Jun, M.D., Ph.D., as Chief Development Officer
Allogene Therapeutics, Inc., a clinical-stage biotechnology company pioneering the development of allogeneic CAR T therapies for cancer, today announced the appointment of Susie Jun, M.D., Ph.D., as Chief Development Officer. Dr. Jun has also served as Senior Director, Hem/Onc Clinical Research, at Gilead, and as Executive Medical Director, Hematol
8/14/18 - Amicus oral Fabry disease drug approved in US [Arab News (Saudi Arabia)]
Amicus Therapeutics first oral drug for the rare condition Fabry disease has been approved by the FDA, giving patients an alternative to conventional injected enzyme replacement therapy. The oral drug is an alternative to the infused enzyme replacement therapy that is current standard of care Sanofi/ Genzymes Fabarazyme. Already approved in Europe,
8/14/18 - Amid pricing spat with U.K. government, Vertex won`t ask NICE to approve its new CF drug [Syrian Arab News Agency]
The battle between Vertex Pharmaceuticals and U.K. health officials over cystic fibrosis drug pricing has reached an impasse after NHS Englands final offer in July. In a statement, Vertex director of external communications Heather Nichols said the company supports the need for robust and fair medicines appraisal in England. Vertex and U.K. health.
8/14/18 - Amneal Pharmaceuticals Inc (NYSE:AMRX) price target raised to $21.00 by Canaccord Genuity
Analyst Ratings For Amneal Pharmaceuticals Inc (NYSE:AMRX) Today, Canaccord Genuity raised its price target on Amneal Pharmaceuticals Inc (NYSE:AMRX) to $21.00 per share. There are 4 Hold Ratings, 4 Buy Ratings, no Strong Buy Ratings, no Sell Ratings on the stock. The current consensus rating on Amneal Pharmaceuticals Inc (NYSE:AMRX) is Buy with a
8/14/18 - AMPIO PHARMACEUTICALS, INC. - 10-Q - Management's Discussion and Analysis of Financial Condition and Results of Operations.
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. This discussion should be read in conjunction with our historical financial statements. For additional information regarding these risks and uncertainties, please see Part II, Item 1 A of this Form 10- Q, "Risk Factors," and the risk factors included in our Annua
8/14/18 - ANGIOGENEX, INC. - 10-Q - Management's Discussion and Analysis of Financial Condition and Results of Operations
This management's discussion and analysis of the financial condition and results of operations of the Company should be read in conjunction with our unaudited condensed consolidated financial statements and accompanying notes for the three and six months ended June 30, 2018 and 2017, which have been prepared in accordance with United States general
8/14/18 - ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2018 Results and Updates Guidance
BAUDETTE- ANI Pharmaceuticals, Inc. ANIP, -1.74% today reported its financial results for the three and six months ended June 30, 2018 and updated its 2018 financial guidance. Arthur S. Przybyl, President and CEO, stated,' In the second quarter of 2018 ANI continued to successfully execute on its strategy to grow the brand and generic business plat
8/14/18 - Aptinyx Reports Second Quarter 2018 Financial and Business Results
Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results and business highlights for the second quarter ended June 30, 2018.. This was a transformational quarter for Aptinyx as we completed a successful IPO that provide
8/14/18 - Aquinox Pharmaceuticals Announces Second Quarter 2018 Financial Results
VANCOUVER- Aquinox Pharmaceuticals, Inc., a pharmaceutical company discovering and developing novel drug candidates to treat inflammation, inflammatory pain, and blood cancers, today provided a corporate update and reported financial results for the second quarter ending June 30, 2018. As a result, we've halted all development activities for rosipt
8/14/18 - ARRAY BIOPHARMA INC - 10-K - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Our future financial condition, as well as any forward-looking statements are subject to significant risks and uncertainties including, but not limited to the factors set forth under the heading "Forward Looking Statements" and "Item 1 A. Risk Factors" under Part I of this Annual Report on Form 10- K, and in other reports we file with the SEC. Ther
8/14/18 - Array BioPharma Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2018
Array BioPharma Inc. today reported results for its fourth quarter and full year of fiscal 2018 and provided an update on the progress of its key commercial products and clinical development programs. "We were thrilled to launch BRAFTOVI?+ MEKTOVI for patients with BRAF- mutant melanoma in the U.S. after receiving FDA approval for the combi
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2018 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2018 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415